Related Experiment Video
Updated: Jan 23, 2026

Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System
Published on: April 23, 2021
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
Meritxell Bellet1, Faten Ahmad2, Rafael Villanueva3
1Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Abstract:
Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.
Related Concept Videos
Heart Failure V: Medical Management
Endocarditis III: Medical Management
Myocarditis III: Medical Management
Pericarditis III: Medical Management
Mitral Stenosis III: Medical Management
Aortic Regurgitation III: Medical Management

